Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India

Table 3 Clinicopathological characteristics of patients who received adjuvant therapy vs those who did not

Patient characteristic	Adjuvant group (n = 117), n (%)	Non-adjuvant Group (n = 30), n (%)	P value
Age, yr (mean)	54.5	60	0.01
Sex (M:F)	47:70	10:20	0.63
Incidental GBC	55 (47)	7 (23.3)	0.03
Neoadjuvant therapy	33 (28.2)	7 (23.3)	0.76
Type of surgery			0.71
Wedge resection	62 (53)	16 (53.3)
Anatomical segment IVb/V resection	48 (41)	11 (36.7)
Modified extended right hepatectomy	7 (6)	3(10)
Histology			0.91
Adenocarcinoma	108 (92.3)	28 (93.3)
Adenosquamous	7(6)	2 (6.7)
Carcinosarcoma	1	0
Squamous	1	0
Histological grade			0.12
Well differentiated	21 (18)	2 (6.7)
Moderately differentiated	82 (70.1)	21 (70)
Poorly differentiated	14 (11.9)	7 (23.3)
pT stage			0.56
T1	6 (5.1)	2 (6.7)
T2	57 (48.7)	11 (36.7)
T3	52 (44.4)	17 (56.6)
T4	2 (1.7)	0
pN stage			0.47
N0	77 (65.8)	17 (56.7)
N+	40 (34.2)	13 (43.3)
LVI positive	37 (31.6)	13 (43.3)	0.32
PNI positive	40 (34.2)	12 (40)	0.7
R0/R1resection			0.84
R0	109 (93.2)	27 (90)
R1	8 (6.8)	3 (10)
Final stage (AJCC 8th)			0.79
I	3 (2.6)	1 (3.3)
II	36 (30.8)	8 (26.7)
III	56 (47.9)	13 (43.3)
IV	22 (18.1)	8 (26.7)

AJCC: American Joint Committee on Cancer; GBC: Gallbladder cancer; LVI: Lymphovascular invasion; PNI: Perineural invasion.